Currency In USD
| Previous Close | 23.07 |
| Open | 23.25 |
| Day High | 24.57 |
| Day Low | 22.53 |
| 52-Week High | 40.37 |
| 52-Week Low | 4.3 |
| Volume | 1.64M |
| Average Volume | 1.16M |
| Market Cap | 1.06B |
| PE | -10 |
| EPS | -2.32 |
| Moving Average 50 Days | 29.25 |
| Moving Average 200 Days | 22.3 |
| Change | 0.14 |
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
GlobeNewswire Inc.
Mar 10, 2026 1:25 PM GMT
Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophyBLA supported by positive pivotal HOPE-3 Phase 3 results, including achievement of the primary endpoint and all
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
GlobeNewswire Inc.
Mar 10, 2026 1:25 PM GMT
Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophyBLA supported by positive pivotal HOPE-3 Phase 3 results, including achievement of the primary endpoint and all
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
GlobeNewswire Inc.
Mar 09, 2026 12:30 PM GMT
– Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET – SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the